Geenen JW - Search Results

1

Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.

Geenen JW, Baranova EV, Asselbergs FW, de Boer A, Vreman RA, Palmer CN, Maitland-van der Zee AH, Hövels AM. Geenen JW, et al. Pharmacogenomics. 2017 Aug;18(12):1143-1153. doi: 10.2217/pgs-2017-0063. Epub 2017 Jul 26. Pharmacogenomics. 2017. PMID: 28745583

2

Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia.

Vreman RA, Geenen JW, Hövels AM, Goettsch WG, Leufkens HGM, Al MJ. Vreman RA, et al. Among authors: geenen jw. Appl Health Econ Health Policy. 2019 Dec;17(6):883-893. doi: 10.1007/s40258-019-00496-1. Appl Health Econ Health Policy. 2019. PMID: 31317510 Free PMC article. Clinical Trial.

3

Accuracy of budget impact estimations and impact on patient access: a hepatitis C case study.

Geenen JW, Boersma C, Klungel OH, Hövels AM. Geenen JW, et al. Eur J Health Econ. 2019 Aug;20(6):857-867. doi: 10.1007/s10198-019-01048-z. Epub 2019 Apr 5. Eur J Health Econ. 2019. PMID: 30953216 Free PMC article.

4

Affordability of oncology drugs: accuracy of budget impact estimations.

Geenen JW, Jut M, Boersma C, Klungel OH, Hövels AM. Geenen JW, et al. J Mark Access Health Policy. 2019 Nov 30;8(1):1697558. doi: 10.1080/20016689.2019.1697558. eCollection 2020. J Mark Access Health Policy. 2019. PMID: 31839908 Free PMC article.

5

Cost of illness of metastatic prostate cancer: a perspective of costs for new treatment options in The Netherlands.

Ter Heine R, Frederix GW, Geenen JW, Hövels AM, van Vulpen M, Kooistra A, De Klerk JM, Bloemendal HJ. Ter Heine R, et al. Among authors: geenen jw. J Comp Eff Res. 2017 Oct;6(7):575-581. doi: 10.2217/cer-2017-0026. Epub 2017 Sep 13. J Comp Eff Res. 2017. PMID: 29091013 Free article.

6

Whole-exome sequencing in intellectual disability; cost before and after a diagnosis.

Vrijenhoek T, Middelburg EM, Monroe GR, van Gassen KLI, Geenen JW, Hövels AM, Knoers NV, van Amstel HKP, Frederix GWJ. Vrijenhoek T, et al. Among authors: geenen jw. Eur J Hum Genet. 2018 Nov;26(11):1566-1571. doi: 10.1038/s41431-018-0203-6. Epub 2018 Jun 29. Eur J Hum Genet. 2018. PMID: 29959382 Free PMC article.

7

A novel method for predicting the budget impact of innovative medicines: validation study for oncolytics.

Geenen JW, Belitser SV, Vreman RA, van Bloois M, Klungel OH, Boersma C, Hövels AM. Geenen JW, et al. Eur J Health Econ. 2020 Aug;21(6):845-853. doi: 10.1007/s10198-020-01176-x. Epub 2020 Apr 4. Eur J Health Econ. 2020. PMID: 32248313 Free PMC article.

8

Increasing the information provided by probabilistic sensitivity analysis: The relative density plot.

Geenen JW, Vreman RA, Boersma C, Klungel OH, Hövels AM, Ham RMTT. Geenen JW, et al. Cost Eff Resour Alloc. 2020 Nov 30;18(1):54. doi: 10.1186/s12962-020-00251-7. Cost Eff Resour Alloc. 2020. PMID: 33292291 Free PMC article.

9

The Application and Implications of Novel Deterministic Sensitivity Analysis Methods.

Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. Vreman RA, et al. Among authors: geenen jw. Pharmacoeconomics. 2021 Jan;39(1):1-17. doi: 10.1007/s40273-020-00979-3. Epub 2020 Dec 14. Pharmacoeconomics. 2021. PMID: 33313990 Free PMC article.

10

Comment on "Deterministic Sensitivity Analysis Under Ignorance".

Vreman RA, Geenen JW, Knies S, Mantel-Teeuwisse AK, Leufkens HGM, Goettsch WG. Vreman RA, et al. Among authors: geenen jw. Pharmacoeconomics. 2021 Oct;39(10):1199. doi: 10.1007/s40273-021-01086-7. Epub 2021 Sep 15. Pharmacoeconomics. 2021. PMID: 34523067 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

11 results

Search Page